Revenue
No reported data
Kyverna Therapeutics, Inc. (KYTX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $133.7M | $112.5M | $49.9M |
| Operating expenses | $169.8M | $142.6M | $62.4M |
| Operating income | −$169.8M | −$142.6M | −$62.4M |
| EBITDAderived | −$168.0M | −$140.5M | −$60.7M |
| Net income | −$161.3M | −$127.5M | −$60.4M |
| Basic EPSper diluted share | -$3.64 | -$3.33 | -$89.61 |
| Diluted EPSper diluted share | -$3.64 | -$3.33 | -$89.61 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 18, 2025Form 4 | SEIDENBERG BETH CDirector | BuyCommon Stock · indirect | 133.3K | $7.50 | $1000.0K | 869.3K |
| Dec 18, 2025Form 4 | Westlake BioPartners Opportunity Fund I, L.P. +3TenPercentOwner | BuyCommon Stock · indirect | 133.3K | $7.50 | $1000.0K | 869.3K |
| Dec 15, 2025Form 4 · 10b5-1 | Walker Karen MarieChief Technology Officer | SellCommon Stock | 24.0K | $12.20 | $292.8K | 22.6K |